Medicare's National Coverage Determinations in Diagnostic Radiology: Examining Evidence and Setting Limits

被引:6
|
作者
Otero, Hansel Javier [1 ,2 ]
Chambers, James D. [2 ]
Bresnahan, Brian W. [3 ]
Kamae, Maki S. [2 ]
Yucel, Kent E. [1 ]
Neumann, Peter J. [2 ]
机构
[1] Inst Clin Res & Hlth Policy Studies, Dept Radiol, Boston, MA 02111 USA
[2] Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA 02111 USA
[3] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA
关键词
Medicare; evidence based medicine; diagnostic imaging; CANCER;
D O I
10.1016/j.acra.2012.05.005
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To systematically review and summarize the Center for Medicare and Medicaid Services (CMS) national coverage determination (NCDs) pertaining diagnostic imaging technologies from 1999 through 2010. Methods: All NCDs pertaining to diagnostic imaging were identified from the Tufts Medical Center NCD database. The variables under study included the quality of the clinical evidence and the final coverage determination. The types of restrictions were categorized. We also categorized the final decisions as "positive coverage" or "no positive/no change in coverage" and assessed the correlation between positive coverage and other variables using Fisher exact test. Results: Twenty-two of 152 (15%) NCDs pertained to diagnostic imaging technologies. The supporting evidence was judge to be good, fair, and poor in 5, 6, and 11 cases, respectively. Eleven technologies (50%) were covered with conditions, four (18%) deferred the coverage decision to local level, and two (9%) were completely not covered. In five instances there was no change to the prior coverage status. Of the 11 decisions resulting in positive coverage, 8 (73%) restricted use to specific population subgroups, 5 (46%) applied restrictions related to treatment, 4 were covered with evidence development, and 2 were restricted to care in specific settings. A significantly higher rate of positive coverage decisions was achieved if the available evidence was good (100% 5/5) or fair (83% 5/6) compared to technologies with poor evidence (10% 1/10) (P < .01). Conclusion: CMS has demonstrated a propensity to limit the use of advanced diagnostic imaging to scenarios in which appropriateness is supported by adequate evidence of clinical utility and improved outcomes with the quality of evidence being a significant factor on final decisions. Understanding the need for high-quality evidence and the types of limitations placed on coverage allows for appropriate planning for the incorporation of diagnostic imaging technologies into clinical practice.
引用
收藏
页码:1060 / 1065
页数:6
相关论文
共 50 条
  • [1] Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations
    Chambers, James D.
    Chenoweth, Matthew
    Cangelosi, Michael J.
    Pyo, Junhee
    Cohen, Joshua T.
    Neumann, Peter J.
    HEALTH AFFAIRS, 2015, 34 (02) : 253 - 260
  • [2] CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY
    Chambers, James D.
    Chenoweth, Matthew D.
    Pyo, Junhee
    Cangelosi, Michael J.
    Neumann, Peter J.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2015, 31 (05) : 347 - 354
  • [3] Funding of evidence included within public comments submitted to inform Medicare national coverage determinations
    Lu, Angela
    Ji, Robin Z.
    Magee, Marley P. D.
    Ross, Joseph S.
    Ramachandran, Reshma
    Redberg, Rita F.
    Dhruva, Sanket S.
    HEALTH AFFAIRS SCHOLAR, 2024, 2 (06):
  • [4] What Is the Level of Evidence Substantiating the Medicare Local Coverage Determinations?
    Chen, Antonia F.
    Bloomfield, Michael R.
    Lichstein, Paul M.
    Yates, Adolph J., Jr.
    Austin, Matthew S.
    JOURNAL OF ARTHROPLASTY, 2015, 30 (03): : 356 - 360
  • [5] Evidence And Medicare's Coverage Of Interventions
    Dhruva, Sanket S.
    Redberg, Rita F.
    HEALTH AFFAIRS, 2015, 34 (06) : 1066 - 1066
  • [6] Evidence And Medicare's Coverage Of Interventions Reply
    Chambers, James D.
    Neumann, Peter J.
    HEALTH AFFAIRS, 2015, 34 (06)
  • [7] Financial Conflicts of Interest in Public Comments on Medicare National Coverage Determinations of Medical Devices
    Lu, Angela
    Ji, Robin Z. Z.
    Ge, Alex Y. Y.
    Ross, Joseph S.
    Ramachandran, Reshma
    Redberg, Rita F.
    Dhruva, Sanket S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (11): : 1094 - 1096
  • [8] Coverage options for promising technologies: Medicare's 'coverage with evidence development'
    Tunis, Sean R.
    Pearson, Steven D.
    HEALTH AFFAIRS, 2006, 25 (05) : 1218 - 1230
  • [9] Medicare's national coverage decisions, 1999-2003: Quality of evidence and review times
    Neumann, PJ
    Divi, N
    Beinfeld, MT
    Levine, BS
    Keenan, PS
    Halpern, EF
    Gazelle, GS
    HEALTH AFFAIRS, 2005, 24 (01) : 243 - 254
  • [10] Assessing Medicare's Coverage With Evidence Development Program
    Mooghali, Maryam
    Moneer, Osman
    Janda, Guneet
    Dhruva, Sanket S.
    Ross, Joseph S.
    Ramachandran, Reshma
    HEALTH AFFAIRS, 2025, 44 (01) : 32 - 39